The ISRO–AIIMS MoU on space medicine signals a new phase in India's human spaceflight ambitions. Examine the significance of space medicine as a field and the institutional challenges India must overcome before the Gaganyaan crewed mission.

Q. The ISRO–AIIMS MoU on space medicine signals a new phase in India's human spaceflight ambitions. Examine the significance of space medicine as a field and the institutional challenges India must overcome before the Gaganyaan crewed mission. (15 marks, 250-350 words)

Space medicine studies human physiology, behaviour and safety under microgravity, radiation and prolonged confinement. The ISRO–AIIMS New Delhi Framework MoU signed in March 2026 [1] converts it from an academic interest into an operational prerequisite for Gaganyaan, whose first crewed flight is targeted for early 2027 [2].

Significance of space medicine as a field - Crew survivability: microgravity causes bone density loss, muscle atrophy and cardiovascular deconditioning. The MoU covers human physiology, immunology, neuroscience, nutrition and musculoskeletal health precisely to build countermeasures [1]. - Strategic autonomy: indigenous medical devices, procedures and protocols reduce dependence on foreign life-support systems — indispensable for the Bharatiya Antariksh Station and crewed lunar missions [1]. - Long-duration capability: radiation biology, biomedical support systems and crew medical kits determine how long Indians can stay in orbit, not merely whether they reach it [3]. - Dual-use terrestrial gains: telemedicine and communication protocols developed for astronauts [3] translate directly into remote-area healthcare delivery. - Institutional model: it marks ISRO's shift from an engineering-centric mission culture to formal clinical-research partnerships.

Institutional challenges before the crewed mission - Thin expertise base: aerospace medicine capacity has rested largely with the IAF's Institute of Aerospace Medicine, which handles crew selection; a civilian clinical research pipeline is only now being created [1]. - Inter-ministerial coordination: the Department of Space (under the PMO) and the Ministry of Health must align funding, timelines and IP-sharing — a framework MoU is an enabler, not an executed programme. - Ethics and regulation: informed consent, risk disclosure and occupational health standards for astronauts remain an unaddressed regulatory space. - Convergence risk: parallel arrangements with AIIMS and SCTIMST [3] need a single roadmap to avoid duplication. - Compressed timelines: an early-2027 flight [2] leaves a narrow window to validate protocols.

Space medicine is therefore the human dimension of a programme long defined by launch vehicles. Converting these MoUs into a funded, ethically governed national space-medicine mission — with dedicated analogue facilities and trained personnel — would let India enter human spaceflight with self-reliant biomedical capability, consistent with the Atmanirbhar Bharat vision that Gaganyaan embodies.

(~325 words)

Sources: 1. ISRO and AIIMS New Delhi sign Framework Memorandum of Understanding for Cooperation in Space Medicine and Research — ISRO — MoU objectives, research areas, BAS/lunar mission linkage, device and protocol development 2. India's first human Space mission "Gaganyaan" programme has entered its final phase — PIB — Gaganyaan final phase and Q1 2027 crewed flight timeline 3. ISRO and SCTIMST Sign Framework MoU to Boost Space Medicine Research — PIB — radiation biology, biomedical support systems, telemedicine protocols, crew medical kits, parallel institutional partnership